Here are the S-3 shelf registrations from Neuraxis, Inc. (NRXS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow NRXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXS filings page.
Neuraxis, Inc. filed Amendment No. 1 to its Form S-3 registration statement (File No. 333-297651) as an exhibit-only filing. The amendment updates Item 16 to add Exhibit 23.1, the consent of Rosenberg Rich Baker Berman, P.A., while leaving the prospectus and the remainder of Part II unchanged.
The document also restates the exhibits list, confirms previously filed legal opinions and powers of attorney, and includes signatures from Chief Executive Officer Brian Carrico and Chief Financial Officer Timothy Henrichs dated July 30, 2026.
Neuraxis, Inc. is registering up to 1,923,194 shares of common stock for resale by existing selling stockholders under a shelf registration. These shares, called the Selling Stockholder Shares, may be sold from time to time at market, negotiated or fixed prices through various methods, including brokered transactions, hedging and short sales, as described in the plan of distribution.
The company will not receive any proceeds from the sale of these shares; all proceeds will go to the selling stockholders, while Neuraxis covers registration-related expenses. As of July 22, 2026, there were 12,477,309 shares of common stock outstanding and the NYSE American closing price was $6.87 per share. The registered shares consist of 849,212 issued shares, 923,776 shares underlying RSUs, and 150,206 shares issued to directors for board service.
Neuraxis is a growth-stage medical technology company focused on neuromodulation therapies for gastrointestinal disorders using its proprietary IB-Stim PENFS device for pediatric and adult functional abdominal pain and its RED rectal expulsion device. The company qualifies as an emerging growth company and directs investors to detailed risk factors in its 2025 Form 10-K and other incorporated SEC filings.